Literature DB >> 6113911

Physiologic disposition of pergolide.

A Rubin, L Lemberger, P Dhahir.   

Abstract

Pergolide, a synthetic ergoline, is a potent long-acting dopaminergic drug effective in Parkinson's disease and amenorrhea-galactorrhea. After 138 micrograms 14C-pergolide orally to healthy subjects, radioactivity was present in plasma and red blood cells. Salivary radioactivity was one third to one tenth that in plasma. Radioactivity in plasma appeared after 15 to 30 min, peaked at 1 to 2 hr, and was barely detectable after 96 hr. Plasma radioactivity was not attributable to pergolide, and the levels did not correlate well with the duration of the prolactin-lowering effect induced by pergolide. Pergolide became bound to several plasma proteins and could not be displaced by other drugs that are also bound or by possible metabolites of pergolide. Radioactivity was eliminated as pergolide metabolites in urine (55%), feces (40%), and breath (5%, as 14CO2).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113911     DOI: 10.1038/clpt.1981.157

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

3.  Pergolide block of the cloned Kv1.5 potassium channels.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-05       Impact factor: 3.000

Review 4.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Authors:  E Flückiger; U Briner; B Clark; A Closse; A Enz; P Gull; A Hofmann; R Markstein; L Tolcsvai; H R Wagner
Journal:  Experientia       Date:  1988-05-15

7.  The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man.

Authors:  M Hümpel; W Krause; G A Hoyer; H Wendt; G Pommerenke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

8.  Pergolide therapy in Parkinson's disease.

Authors:  P Jeanty; M Van den Kerchove; A Lowenthal; H De Bruyne
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.